Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Idenix Pharmaceuticals' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Stock quotes in this article: IDIX 

Idenix Pharmaceuticals (IDIX)

Presentation at Morgan Stanley Global Healthcare Conference

September 10, 2012 1:15 p.m. ET

Executives

Ronald Renaud - President and CEO

Douglas Mayers - EVP and Chief Medical Officer

Analysts

David Friedman - Morgan Stanley

Presentation

David Friedman - Morgan Stanley

Thanks everyone for joining. Dave Friedman, biotech analyst here at Morgan Stanley. And for disclosure purposes, Morgan Stanley as well as personal holdings disclosures are available at morganstanley.com/researchdisclosures.

And I’m happy to have the team from Idenix up here. On the far side, Doug Mayers, chief medical officer; and on the nearside, Ron Renaud, president and CEO. And we’d look for this to be interactive and so any questions, anyone feel free to raise their hand. We’ll make sure we get to you. If I don’t see you, just yell or something and we’ll make sure.

My guess is most people know the company, but maybe for the one or two that don’t, if you can just give a couple minute overview of who you guys are and what you guys have going on?

Ronald Renaud

First of all, thanks for having us. Idenix is a company focused on developing antivirals. Right now our singular focus is on direct-acting antivirals for the treatment of hepatitis C. We have taken a nucleoside across the finish line in hepatitis B, and that drug is now sold by Novartis. We did that in our previous collaboration with Novartis, and that drug is now on the market and sold in more than 60 countries worldwide.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,384.61 49.33 0.32%
NASDAQ 3,500.10 3.67 0.10%
S&P 500 1,669.43 3.14 0.19%
US 10 Yr 1.954% -0.011

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs